.Pharmacolibrary.Drugs.ATC.A.A10BJ06_1

Information

name:Semaglutide_1
ATC code:A10BJ06_1
route:oral
n-compartments2

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated for the treatment of type 2 diabetes mellitus and chronic weight management. It is currently approved for clinical use in both oral and subcutaneous injectable formulations.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy subjects after oral administration of semaglutide tablets.

References

  1. Overgaard, RV, et al., & Kildemoes, RJ (2021). Clinical Pharmacokinetics of Oral Semaglutide: Analyses of Data from Clinical Pharmacology Trials. Clinical pharmacokinetics 60(10) 1335–1348. DOI:10.1007/s40262-021-01025-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/33969456

  2. Yang, XD, & Yang, YY (2024). Clinical Pharmacokinetics of Semaglutide: A Systematic Review. Drug design, development and therapy 18 2555–2570. DOI:10.2147/DDDT.S470826 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38952487

  3. Clements, JN, et al., & Gambill, K (2021). Pharmacokinetics and Clinical Implications of Oral Semaglutide for Type 2 Diabetes Mellitus. Clinical pharmacokinetics 60(2) 153–163. DOI:10.1007/s40262-020-00951-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/33108617

Revisions

Generated at 2025-07-21T18:21:10Z by OpenModelicaOpenModelica 1.25.1 using GenerateDoc.mos